Related Experiment Video
Updated: May 7, 2026
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
New non-symmetrical choline kinase inhibitors
Santiago Schiaffino-Ortega1, Luisa Carlota López-Cara, Pablo Ríos-Marco
1Departamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja s/n, Universidad de Granada,18071 Granada, Spain.
Bioorganic & Medicinal Chemistry
|October 2, 2013
Summary
Researchers developed novel anticancer agents targeting choline kinase (ChoK). Compounds 3f and 4f showed promise as ChoK inhibitors, while 3c, 3d, and 4c demonstrated potent antiproliferative effects.
Area of Science:
- Pharmacological research
- Medicinal chemistry
- Cancer biology
Background:
- Choline kinase (ChoK) is crucial for phosphatidylcholine synthesis, a key component of cell membranes.
- Dysregulation of the CDP-choline pathway is implicated in cancer development.
- Novel and selective anticancer agents targeting ChoK are needed.
Purpose of the Study:
- To design and synthesize a new family of non-symmetrical monocationic compounds as potential anticancer agents.
- To identify selective choline kinase (ChoK) inhibitors and antiproliferative compounds.
Main Methods:
- Synthesis of novel non-symmetrical monocationic compounds featuring a 3-aminophenol moiety.
- Incorporation of 4-(dimethylamino)- or 4-(pyrrolidin-1-yl)pyridinium cationic heads via various linkers.
- Evaluation of compounds for choline kinase (ChoK) inhibition and antiproliferative activity.
Main Results:
- Compounds 3f and 4f were identified as the most promising choline kinase (ChoK) inhibitors.
- Compounds 3c, 3d, and 4c exhibited significant antiproliferative activity.
- Structure-activity relationships were analyzed to guide further drug design.
Conclusions:
- The developed series of compounds offers a promising platform for designing novel anticancer agents.
- Specific compounds show potential as both direct enzyme inhibitors and cytotoxic agents.
- Further optimization could lead to more potent and selective therapeutic candidates.
Related Concept Videos
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...